Adaptimmune Therapeutics (ADAP)

Earnings in 2024 (TTM): -₹6.26 Billion

According to Adaptimmune Therapeutics's latest financial reports the company's current earnings are ₹0.14 Billion. In 2023 the company made an earning of -₹9.61 Billion, an increase over its 2022 earnings that were of -₹13.64 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Adaptimmune Therapeutics from 2016 to 2024

Annual earnings

Year	Earnings	Change
2024 (TTM)	-₹6.26 Billion	-34.88%
2023	-₹9.61 Billion	-29.58%
2022	-₹13.64 Billion	-0.36%
2021	-₹13.69 Billion	21.62%
2020	-₹11.26 Billion	-4.55%
2019	-₹11.8 Billion	69%
2018	-₹6.98 Billion	-7.47%
2017	-₹7.54 Billion	24.71%
2016	-₹6.05 Billion

Earnings for similar companies or competitors

Company	Earnings	Earnings differencediff.	Country
Novavax NVAX	-₹23.09 Billion	264.00%	🇺🇸 USA
Enzo Biochem ENZ	-₹0.83 Billion	-86.94%	🇺🇸 USA
uniQure QURE	-₹24.73 Billion	289.86%	🇳🇱 Netherlands
Exelixis EXEL	₹50.60 B	-897.99%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Earnings for Adaptimmune Therapeutics (ADAP)

Earnings in 2024 (TTM): -₹6.26 Billion